Amylyx Pharmaceuticals, Inc. (AMLX)
Healthcare
Pharmaceuticals
Methodology Breakdown
Pre-revenue clinical-stage biotech. The appropriate methodology — risk-adjusted pipeline NPV — is shipping in a future sprint. The Cash Floor below is shown as a structural reference, not a fair-value target. Investors aren't pricing this stock for the cash; they're pricing optionality on the pipeline.
| Method | Value | Role |
|---|---|---|
| Peer Multiples | $2.85 | REFERENCE |
| Book Value Anchor | $4.93 | REFERENCE |
| Cash Floor | $1.77 | REFERENCE |
| NAV Anchor | $4.93 | REFERENCE |
Verdict basis:
cash_floor_only
Health Score
Health Score
48
Out of 100
Mixed
Pillar Scores
Financial Strength
50
Operating Trend
40
Valuation
40
Capital Allocation
50
Risk Management
80
Positives
↑
Strong liquidity — current assets more than 2× current liabilities
+1.3
Concerns
↓
Negative ROIC — business destroying value on invested capital
-2.5
↓
Low FCF yield — below 1%, price implies exceptional future growth
-2.5
↓
Piotroski F-Score 0–3 — multiple financial weakness signals
-1.3
Signal contribution:
+1.3 from strengths
-6.3 from concerns
Health Score Trend
7 snapshots
Financials
TTM Financials
| Revenue Total sales generated from the company's primary business activities over the trailing twelve months. | $0 |
| Gross Profit Revenue minus cost of goods sold. What remains before operating expenses — reflects pricing power and production efficiency. | — |
| Operating Income Profit from core business operations after all operating expenses (EBIT). Excludes interest and taxes. | -159.3M |
| Net Income Bottom-line profit after all expenses, interest, and taxes are deducted from revenue. | -150.1M |
| Free Cash Flow Operating cash flow minus capital expenditures. The actual cash the business generates after maintaining its assets — the truest measure of profitability. | -120.5M |
| EBITDA Earnings before interest, taxes, depreciation & amortization. A proxy for operating cash earnings that strips out accounting and financing differences. | -158.8M |
| Total Debt Combined short-term and long-term interest-bearing debt obligations. Compare against cash and earnings to gauge leverage risk. | — |
| Cash & Equivalents Highly liquid assets on hand — cash, money market funds, and short-term securities. The company's immediate financial cushion. | 229.1M |
Valuation
| Market Cap | 1.47B |
| Enterprise Value | 1.25B |
| EV / Revenue | — |
| EV / EBITDA | -7.9x |
| P/E (TTM) | -9.8x |
| Forward P/E | — |
| PEG | — |
| P/FCF | -12.2x |
| FCF Yield | -8.2% |
P/Book vs history — 83% percentile
(historically expensive)
CheapMidExpensive
Relative Valuation
Negative FCF (-120.5M TTM) — using relative multiples instead of DCF
Book Value / Share
$2.47
Price / Book
5.4x
Key Metrics
| Gross Margin Gross profit as a % of revenue. Measures how efficiently the company produces its goods or services — higher is better. | — |
| EBITDA Margin EBITDA as a % of revenue. Shows core operating profitability before accounting adjustments — useful for comparing across industries. | — |
| Net Margin Net income as a % of revenue. The ultimate measure of overall profitability after every expense, interest payment, and tax is accounted for. | — |
| FCF Margin Free cash flow as a % of revenue. Shows how much of each dollar of revenue converts into real, spendable cash. | — |
| Revenue Growth (YoY) Year-over-year change in total revenue. Measures business momentum — sustained growth above 15% is typically considered strong. | 100.0% |
| Net Income Growth (YoY) Year-over-year change in net income. Shows whether profits are growing faster or slower than revenue — a key indicator of improving or deteriorating quality. | 31.4% |
| Piotroski F-Score Score from 0–9 measuring financial strength across profitability, leverage, and efficiency signals. 8–9 = strong, 0–2 = distressed. | 4 / 9 |
| Altman Z-Score Bankruptcy risk model. Above 2.99 = safe zone, 1.81–2.99 = grey zone, below 1.81 = distress signal. Most useful for manufacturing companies. | 8.63 |
Community Sentiment
Not enough ratings yet.
Be the first to rate this company below.
Be the first to rate this company below.
Quarterly Financials
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '23 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Total quarterly sales from primary business operations. | — | $0 | $0 | $0 | $0 | -$665,000 | $416,000 | -1.0M | 88.6M | 108.4M | 102.7M | 98.2M |
| Gross Profit Quarterly revenue minus cost of goods sold. | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income Quarterly profit from core operations before interest and taxes (EBIT). | -43.8M | -36.6M | -36.0M | -42.9M | -37.8M | -40.7M | -75.7M | -76.3M | -122.1M | 1.9M | 18.7M | 20.2M |
| Net Income Quarterly bottom-line profit after all expenses and taxes. | -41.3M | -33.0M | -34.4M | -41.4M | -35.9M | -37.5M | -72.7M | -72.7M | -118.8M | 4.7M | 20.9M | 22.1M |
| FCF Quarterly free cash flow: operating cash minus capital expenditures. | -36.9M | -28.0M | -30.4M | -25.3M | -39.8M | -59.0M | -41.6M | -66.7M | -$556,000 | 13.2M | -5.5M | 8.3M |
Revenue & Free Cash Flow
Want to track AMLX in your own watchlist?
Create a free account to save companies, refresh fundamentals on demand,
and record your investment thesis.
Sign up free
Get stocks like AMLX in your inbox every Sunday
11 sector-leading stocks delivered to your inbox every Sunday. Free.
No spam. Unsubscribe anytime.
Disclaimer: This analysis is for informational purposes only and does not constitute
investment advice. Scores and valuations are derived from SEC filings and publicly available data.
Always do your own research before making investment decisions.
Track AMLX in your watchlist
Free account · save companies, refresh on demand
Sign up free